Provided by Tiger Fintech (Singapore) Pte. Ltd.

ITT Inc.

149.41
+6.244.36%
Pre-market: 149.03-0.3800-0.25%07:59 EDT
Volume:499.21K
Turnover:74.49M
Market Cap:11.76B
PE:23.79
High:150.04
Open:148.13
Low:147.50
Close:143.17
Loading ...

ITT Q4 Adj $1.50 Beats $1.47 Estimate, Sales $929.00M Beat $928.42M Estimate

Benzinga
·
06 Feb

ITT Inc - Increases Quarterly Dividend by 10% to $0.351 per Share

THOMSON REUTERS
·
06 Feb

ITT Inc - Initiates 2025 EPS Guidance of $6.05 to $6.45

THOMSON REUTERS
·
06 Feb

ITT Inc FY2025 REV View $3.88 Bln -- Lseg Ibes Data

THOMSON REUTERS
·
06 Feb

ITT Inc Outlook 2025 Revenue Growth of 2% to 4%, up 3% to 5% on an Organic Basis

THOMSON REUTERS
·
06 Feb

BRIEF-ITT Q4 Adjusted EPS USD 1.5 Vs. IBES Estimate USD 1.47

Reuters
·
06 Feb

ITT Reports Fourth Quarter Earnings Per Share (EPS) of $1.55, Adjusted EPS of $1.50; Reports Full Year EPS of $6.30, Adjusted EPS of $5.86

Business Wire
·
06 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
06 Feb

ITT Earnings: What To Look For From ITT

StockStory
·
05 Feb

Gabelli Funds to Host Pump, Valve & Water Systems Symposium at the Harvard Club, New York City

GlobeNewswire
·
04 Feb

Is ITT Inc. (NYSE:ITT) Trading At A 20% Discount?

Simply Wall St.
·
03 Feb

Investors in ITT (NYSE:ITT) have seen splendid returns of 132% over the past five years

Simply Wall St.
·
02 Feb

LXU or ITT: Which Is the Better Value Stock Right Now?

Zacks
·
01 Feb

ITT (ITT) Reports Next Week: Wall Street Expects Earnings Growth

Zacks
·
30 Jan

Gabelli Funds to Host Pump, Valve & Water Systems Symposium at the Harvard Club, New York City

GlobeNewswire
·
30 Jan

ITT Announces Participation at Upcoming Investor Conferences in February

Business Wire
·
29 Jan

IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25…

Zacks Small Cap Research
·
28 Jan

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

PR Newswire
·
28 Jan

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

Benzinga
·
27 Jan

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

GlobeNewswire
·
27 Jan